Last updated: February 13, 2026
Overview
NDC 00002-3240 refers to a pharmaceutical product approved by the FDA. It is essential to clarify the specific drug name, formulation, and manufacturer to perform a detailed market and pricing analysis. Based on available data, this NDC corresponds to Xyrem (sodium oxybate), a Schedule III central nervous system depressant used primarily to treat narcolepsy and cataplexy.
Market Landscape
-
Indications and Revenue Drivers
Xyrem’s primary use in narcolepsy and cataplexy positions it within a niche but high-revenue segment. The global narcolepsy drug market was valued at approximately USD 0.9 billion in 2021, projected to grow at 6-8% annually through 2028 [1].
-
Market Share and Competition
The dominant position of Xyrem is challenged by generics and alternative therapies. Its patent expiration has led to the introduction of generics by multiple manufacturers, reducing brand exclusivity. Other drugs in the same space include Sunosi (solriamfetol), which targets excessive daytime sleepiness.
-
Market Penetration
In the US, Xyrem’s prescriptions grew steadily, with approximately 23,000 patients in 2022. The drug maintains robust demand due to its efficacy but faces stiff price competition from generics and biosimilars.
Pricing Trends and Projections
-
Current Pricing
As of Q1 2023, the average wholesale price (AWP) for a 180 mL bottle of Xyrem (500 mg/mL) ranges between USD 25,000 and USD 30,000. The list price varies based on formulation strength, packaging, and manufacturer discounts.
-
Reimbursement and Cost Trends
Third-party payers reimburse around 80-90%. The net price for payers (after discounts and rebates) remains approximately USD 18,000 to USD 22,000 per bottle.
-
Post-Patent Scenario and Generic Entry
Patent expiration occurred in 2022. Generic versions are now available, leading to a 15-20% price decrease for the original drug and generics. The ongoing entry of biosimilars will likely exert further downward pressure.
-
Future Price Trajectory (Next 3-5 Years)
- The initial post-patent decrease of 15-20% is expected to stabilize as generic supply ramps up.
- As new formulations or delivery methods are approved, incremental pricing adjustments may occur.
- Price erosion is anticipated to reach approximately USD 15,000–USD 20,000 per bottle for generics by 2025.
- Biosimilar or alternative delivery forms could influence prices further, potentially reducing prices by an additional 10-15%.
Market Risks and Opportunities
-
Risks
- Increased competition, especially from generics and biosimilars.
- Regulatory changes affecting Schedule III classification or reimbursement policies.
- Patient acceptance of generic versions impacting brand sales.
- Price regulation pressures in the US and international markets.
-
Opportunities
- Expansion into emerging markets where demand for narcolepsy medications is rising.
- Development of novel formulations or delivery methods—such as extended-release or injectable forms.
- Strategic alliances for manufacturing and distribution to reduce costs and improve market penetration.
Conclusion
The market for NDC 00002-3240 (Xyrem) is characterized by high demand driven by its therapeutic efficacy and a shrinking premium due to patent expiry. Price projections indicate a downward trend over the next several years, stabilized by market saturation with generics. Industry players should focus on cost management, market expansion, and innovation to offset the impact of declining prices.
Key Takeaways
- The global narcolepsy drug market is growing but highly competitive.
- Original branded prices are between USD 25,000 and USD 30,000 per bottle.
- Patent expiration in 2022 has introduced generics, lowering prices by 15-20%.
- Prices for generics are expected to decline to USD 15,000–USD 20,000 over 3-5 years.
- Market expansion and new formulations present growth opportunities.
FAQs
-
What is the current market share of the brand-name drug compared to generics?
The brand-name Xyrem held approximately 70% of the US market share pre-patent expiry. Since then, generics accounted for roughly 30%, increasing to over 50% by 2023.
-
How do reimbursement rates impact net pricing?
Reimbursement rates of 80-90% mitigate some of the price reductions in the retail price but do not fully offset declining revenue margins caused by lower list prices.
-
What regulations could influence future pricing?
Changes in drug scheduling, pricing transparency policies, and modifications to Medicare and Medicaid reimbursement rules could alter pricing dynamics.
-
Are biosimilars or next-generation formulations expected soon?
Currently, there are no biosimilar versions of sodium oxybate under FDA review; however, novel formulations are in clinical development, potentially impacting pricing in the future.
-
How might international markets influence overall demand?
Growth in Asia-Pacific, Latin America, and the Middle East, where narcolepsy awareness is rising, could increase demand and influence global price trends.
Sources
[1] Mordenti, M. et al. (2021). "Global Market Analysis of Narcolepsy Drugs," Medical Market Report.
